People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| StemoniX, Inc. | — | Biotechnology | Series A | $14.6M | $3.6M | 2019 |
| Cns Therapeutics Inc | — | Pharmaceuticals | Series A | $13.1M | $94.5M | 2010 |
Andrew LaFrence at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew LaFrence on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| John Foster | 1 | 10 |
| Peter McNerney | 1 | 6 |
| Pratik Shah | 1 | 5 |
| Howard Rosen | 1 | 5 |
| Yung-Ping Yeh | 1 | 4 |
| Marcus Boehm | 1 | 3 |
| Murdoc Khaleghi | 1 | 2 |
| Ryan Gordon | 1 | 2 |
| Steven Snyder | 1 | 2 |
| Robert Petcavich | 1 | 2 |
| Paul Hansen | 1 | 2 |
| Richard Penn | 1 | 2 |
| Sriram Nadathur | 1 | 1 |
| Patrick O'Shaughnessy | 1 | 1 |
| Blake Anson | 1 | 1 |
| David Buche | 1 | 1 |
| Fabian Zanella | 1 | 1 |
| Matthew Peris | 1 | 1 |
| Dimas Jimenez | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.